Page 20 - Breakthrough Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Additional data from recently reported positive Phase 3 RESILIENT trial will be presentedCHATHAM, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer, will present at The 6th International Congress on Controversies in Fibromyalgia in Brussels, Belgium on March 7, 2024. The pres

The FDA has granted Breakthrough Therapy designation to latozinemab (AL001) for the treatment of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN).

In the news release, NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock, issued 27-Feb-2024 by NRx Pharmaceuticals, Inc. over PR Newswire, we...

New to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Series...

WAINUA™ approved with launch underway; on track for EU and Canada approval decisions this year Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE,...